Anlon healthcare Limited has successfully completed its bonus share allotment process, marking a significant milestone in the company's capital structure enhancement. The pharmaceutical company announced the completion of its 1:1 bonus equity share allotment on April 27, 2026, effectively doubling the shareholding for all eligible investors.

Bonus Share Allotment Details

The company's Board of Directors, in their meeting held on April 27, 2026, formalized the allotment of bonus equity shares to eligible shareholders. The allotment was executed with precision, targeting shareholders whose names appeared in the Register of Members and Register of Beneficial Owners as of the designated record date.

Impact on Share Capital Structure

The bonus share allotment has substantially transformed Anlon Healthcare's capital structure. The company has effectively doubled its equity base through this corporate action, providing existing shareholders with additional shares without any cash outflow.

Regulatory Compliance and Documentation

The bonus share allotment was conducted in full compliance with regulatory requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously communicated with stakeholders through intimations dated March 6, 2026, April 8, 2026, and April 9, 2026, ensuring complete transparency throughout the process.

The formal documentation was signed by Punitkumar Rasadia, Managing Director (DIN: 06696258), with digital authentication completed on April 27, 2026, at 09:22:11 +05'30'. The efficient board meeting, lasting merely 15 minutes, demonstrates the company's streamlined decision-making processes and corporate governance standards.

Shareholder Benefits

Eligible shareholders who held shares as of April 24, 2026, have received one additional equity share for every share held, effectively doubling their shareholding in Anlon Healthcare Limited. This bonus issue enhances liquidity and makes shares more accessible to retail investors while maintaining proportional ownership rights for all existing shareholders.

Anlon healthcare Limited has received confirmation from both major depositories regarding the new ISIN allocation for its upcoming equity share subdivision. The company had earlier announced the subdivision of its equity shares with a record date of April 24, 2026.

Share Subdivision Details

The company is proceeding with the subdivision of its existing equity shares, converting each share with a face value of Rs. 10 into 5 shares with a face value of Rs. 2 each. The depositories NSDL and CDSL have confirmed the allocation of the new ISIN for the subdivided shares.

Depository Confirmations

Both major depositories have confirmed the activation of the new ISIN. Central Depository Services (India) Limited (CDSL) activated the ISIN INE0Y8W01025 on April 17, 2026. The activation was confirmed through their communication dated April 17, 2026, reference number CDSL/ISS/RB/49404.

National Securities Depository Limited (NSDL) also confirmed the ISIN activation on April 20, 2026, through their communication reference NSDL/II/DR/JNG/1058/2026. NSDL's confirmation included details about the registrar arrangement for the new shares.

Registrar and Implementation

KFIN Technologies Limited, with Registrar ID IN200800, has been designated as the registrar for the new equity shares. The subdivision will take effect under the new ISIN from the record date of April 24, 2026.

The company has informed both BSE Limited (Scrip Code: 544497) and National Stock Exchange of India Limited (Scrip Code: AHCL) about the new ISIN allocation and the upcoming subdivision implementation.